EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, and Innovent Biologics, one of the leading biopharmaceutical companies in China, have formed a multiple target agreement for the development of bispecific antibodies. Innovent will gain access to EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to develop multiple bispecific antibodies for the Chinese market, including the right to out-license the developed p...